Adalimumab-Adbm
3 NDCs across 2 manufacturers|2 Generic,1 Brand
Adalimumab-Adbm is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $61 million on Adalimumab-Adbm across 8,014 claims for 1,579 beneficiaries.
Adalimumab-Adbm is available as 3 NDCs from 2 manufacturers (2 generic, 1 brand), with NADAC prices from $639.19 to $3202.75 per EA — the most expensive product costs about 5.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
2G / 1B
Manufacturers
2
competing in market
Price Spread
$639.19 – $3202.75
per EA
7d Activity
avg +0.1% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing ADALIMUMAB-ADBM
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
CYLTEZO(CF) PEN 40 MG/0.8 ML | $3202.7520 per EA | — |
ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML | $639.1946 per EA | +0.06% |
ADALIMUMAB-ADBM(CF) PEN 40 MG/0.4 ML | $639.1946 per EA | +0.06% |
Frequently Asked Questions
What is Adalimumab-Adbm used to treat?
Adalimumab-Adbm is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Adalimumab-Adbm?
In 2024, Medicare Part D spent $61 million on Adalimumab-Adbm across 8,014 claims for 1,579 beneficiaries.
How many Adalimumab-Adbm products are on the market?
The Adalimumab-Adbm drug market contains 3 NDCs from 2 manufacturers — 2 generic and 1 brand product.
What is the price range for Adalimumab-Adbm?
NADAC reference prices for Adalimumab-Adbm range from $639.1946 to $3202.7520 per EA — the most expensive product costs about 5.0× the cheapest.
Is generic Adalimumab-Adbm cheaper than brand?
The average generic NADAC for Adalimumab-Adbm is $639.1946 per EA, versus $3202.7520 for brand-labeled products — brand versions average about 5.0× the generic price.
Which manufacturers make Adalimumab-Adbm?
2 manufacturers list Adalimumab-Adbm in NADAC. Ranked by number of NDCs, the largest are Boehringer Ingelheim Pharmaceuticals Inc. (2), Quallent Pharmaceuticals Health LLC (1).
How has the price of Adalimumab-Adbm changed recently?
Over the past 7 days, 2 Adalimumab-Adbm NDCs rose and 0 fell, with a market-wide average change of +0.1%.